Vitamin D supplementation to persistent carriers of MRSA-a randomized and placebo-controlled clinical trial.
Eur J Clin Microbiol Infect Dis. 2018 Sep;37(9):1735-1744. doi: 10.1007/s10096-018-3306-7.
Björkhem-Bergman L1,2, Missailidis C3,4, Karlsson-Valik J5, Tammelin A5, Ekström L6, Bottai M7, Hammar U7, Lindh G8, Bergman P9,10.
Many studies have found MRSA to be associated with a poor Vitamin D Receptor
Resveratrol is one of the ways to activate the Vitamin D receptor
and thus get more Vitamin D to the tissues
In this study the vitamin D level in the blood was raised to a good level of 40 ng,
which is normaly enough to have a benefit
however the tissues containing the MRSA apparently did not get much
The risk of 40 diseases at least double with poor Vitamin D Receptor as of July 2019
Vitamin D Receptor table shows what compensates for low VDR activation
Compensate for poor VDR by increasing one or more:
| Increasing | Increases |
| 1) Vitamin D supplement Sun Ultraviolet -B | Vitamin D in the blood and thus in the cells |
| 2) Magnesium | Vitamin D in the blood AND in the cells |
| 3) Omega-3 | Vitamin D in the cells |
| 4) Resveratrol | Vitamin D Receptor |
| 5) Intense exercise | Vitamin D Receptor |
| 6) Get prescription for VDR activator paricalcitol, maxacalcitol? | Vitamin D Receptor |
| 7) Quercetin (flavonoid) | Vitamin D Receptor |
| 8) Zinc is in the VDR | Vitamin D Receptor |
| 9) Boron | Vitamin D Receptor ?, etc |
| 10) Essential oils e.g. ginger, curcumin | Vitamin D Receptor |
| 11) Progesterone | Vitamin D Receptor |
| 12) Infrequent high concentration Vitamin D Increases the concentration gradient | Vitamin D Receptor |
| 13) Sulfroaphane and perhaps sulfur | Vitamin D Receptor |
| 14) Butyrate especially gut | Vitamin D Receptor |
| 15) Berberine | Vitamin D Receptor |
Note: If you are not feeling enough benefit from Vitamin D, you might try increasing VDR activation. You might feel the benefit within days of adding one or more of the above
Note: 2 ways to Improve activation of the Vitamin D Receptor:
1) Adding Reveratrol
2) Taking the vitamin D infrequently (~every two weeks) instead of daily
See MRSA, Vitamin D Receptor and Resveratrol
- "Vitamin D's potential to reduce the risk of hospital-acquired infections" - 2012 - Vit D Receptor
- "Staphylococcus aureus nasal carriage is associated with serum 25-hydroxyvitamin D levels, gender and smoking status. The Tromsø Staph and Skin Study" 2012 10.1007/s10096-011-1331-x "RECEPTOR" occurs 7 times
- Search web for MRSA resveratrol 96,000 as of July 2019
- Search web for MRSA "vitamin d receptor" 17,500 items as of July 2019
- "Resveratrol: A Double-Edged Sword in Health Benefits" Sept 2018 Download the PDF from VitaminDWiki
- Adaptive and innate immune system, vitamin D genes, and Rheumatoid Arthritis – June 2019 VItaminDWiki
- Rheumatoid Arthritis helped by Reseveratrol and/or infrequent Vitamin D - similar to MRSA
- TB and Leprosy are easily confused and associated with Vitamin D Receptor like MRSA. they both have been treated by Antibiotics and things which increase the Vitamin D Receptor
Unknown for MRSA
Poor Receptor ==> MRSA OR MRSA ==> Poor Receptor
Whereas for several Cancers
Cancer ==> Poor Vitamin D Receptor that is, a Cancer has learned how to deactive the local VDR
Download the PDF from VitaminDWiki
Methicillin-resistant Staphylococcus aureus (MRSA) is resistant to all beta-lactam antibiotics and can cause severe infections that are difficult to treat. Eradication strategies with conventional antibiotics are not always effective and alternative approaches are warranted. Here, we tested the hypothesis that daily supplementation with vitamin D for 12 months would reduce MRSA carriage rates among a group of persistent carriers. This was a double-blind, placebo-controlled randomized trial with n = 65 persistent MRSA carriers with 25-hydroxy vitamin D3 (25OHD) < 75 nmol/L, who were followed up with bacterial cultures at baseline and every 3 months for 1 year. The primary endpoint was the decline in MRSA positivity during the study period. The study was conducted in two MRSA outpatient clinics at the Karolinska University Hospital, Stockholm, Sweden. In total, n = 65 persistent MRSA carriers were randomized and n = 3 were lost to follow-up. Only patients deficient in vitamin D (< 75 nmol/L) were included. Vitamin D (4000 IU) or placebo/day was administered for 12 months. The decline in MRSA positivity was equal in the vitamin D and placebo group during the study period (OR, 1.00; 95% CI, 0.97-1.03; p = 0.928) and approximately 40% in both groups were MRSA-negative after 12 months. The vitamin D group produced 103 positive cultures out of 318 cultures (32.4%) from nose, throat, and perineum over the study period, whereas the placebo group produced 135/393 positive cultures (34.0%) (Fisher's exact test, p = 0.94). Vitamin D supplementation did not influence MRSA carriage. Thus, available data does not support vitamin D supplementation to persistent MRSA carriers.
Trial registration: www.clinicaltrials.gov ; NCT02178488.